ClinicalTrials.gg
Active, not recruitingNCT04034810FIRSTUpdated Sep 29, 2026

Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment

An observational study in Intracranial Aneurysm and Flow Diverter, sponsored by Balt Extrusion. Active, not recruiting at 29 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Balt Extrusion · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
234
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Intracranial Aneurysm with a site in France — 19 open to participants now, 26 under way, 1 of them phase 3. Intracranial Aneurysm · France.

Planned enrollment
20th of 43
234 · median 206
Started
2019
with 4 others
Observational
43 of 66
10 open now
Primary completion
2023-03
later than 0 of 25 live
Registered
37th of 66
by date
Lead sponsor
3 of 66
Balt Extrusion

Among the 66 studies in Intracranial Aneurysm with a site in France, this one is the 20th largest by planned enrollment of the 43 observational ones that give a count, is one of 5 that started in 2019, is one of 43 observational ones, reaches primary completion later than 0 of the 25 other live ones, and was the 37th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

19 of the 66 studies in Intracranial Aneurysm with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Intracranial Aneurysm with a site in France, or all of them as a file.
02

Study summary

The FIRST study is an observational, prospective, multi-center, international, single-arm, study. The aim of the study is to collect safety and efficacy information on the use of the silk vista and silk vista baby flow diverter in order to assess clinical safety and performance of the device for treating intracranial aneurysms.

All patients with intracranial aneurysm ruptured or unruptured, whatever the localization of the aneurysm, and treated with silk vista or silk vista baby, will be consecutively enrolled in the study.

The patient's inclusion and follow up in the study will occur as part of their usual standard of care.

03

Conditions studied

  • Intracranial Aneurysm
  • Flow Diverter

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with an intracranial aneurysm treated with silk vista and silk vista baby.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with intracranial aneurysms intended to be treated with the silk vista and silk vista baby (decision of use silk vista and silk vista baby is done independently and prior to the participation of the patient in the study)
  2. Patients with recanalized aneurysms previously treated with coils exclusively are also eligible.
  3. In case of multiple aneurysms, only treatment with silk vista and silk vista baby are allowed (between the initial index procedure to the 12 months follow up visit)
  4. Patient ≥ 18 years, who signed an .

Exclusion criteria

Exclusion Criteria:

  1. Patient presenting with to the use of silk vista and silk vista babyaccording to the IFU (Instruction for Use).
  2. Recanalized aneurysms initially treated with stent (including stent assisted coiling)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
234 participants (estimated)
Patient registry
No

Interventions

  • DeviceIntracranial aneurysm treated with Silk vista and silk vista baby

    Patients with intracranial aneurysm(s) intended to be treated with the silk vista and silk vista baby according to standard of care.

06

What researchers measure

Primary outcomes

  1. Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.

    Characterized by the rate of the permanent neurologic deficits and procedure related mortality.

    Time frame: At 12-months (-3 / + 6 months) post procedure

  2. Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.

    Characterized by the clinical outcome assessed by mRS of the permanent neurologic deficits and procedure related mortality.

    Time frame: At 12-months (-3 / + 6 months) post procedure

Secondary outcomes

  1. Safety of silk vista and silk vista baby

    Assessed by the rate of adverse events

    Time frame: At T0

  2. Safety of silk vista and silk vista baby

    Assessed by the rate of adverse events

    Time frame: At hospital discharge

  3. Safety of silk vista and silk vista baby

    Assessed by the rate of adverse events

    Time frame: Up to 30 days (-10 / + 21 days) post- procedure.

  4. Safety of silk vista and silk vista baby

    Assessed by the rate of adverse events

    Time frame: At 6 months (-2/+3 months) post- procedure.

  5. Safety of silk vista and silk vista baby

    Assessed by the rate of adverse events

    Time frame: At 12 months (-3/+6 months) post- procedure.

  6. Safety of silk vista and silk vista baby

    Assessed by the rate of adverse events

    Time frame: At 3 years post procedure

  7. Safety of silk vista and silk vista baby

    Assessed by the rate of adverse events

    Time frame: At 5 years post procedure

  8. Efficacy of silk vista and silk vista baby

    Assessed by aneurysm occlusion rate

    Time frame: At T0

  9. Efficacy of silk vista and silk vista baby

    Assessed by aneurysm occlusion rate

    Time frame: At hospital discharge

  10. Efficacy of silk vista and silk vista baby

    Assessed by aneurysm occlusion rate

    Time frame: Up to 30 days (-10 / + 21 days) post- procedure.

  11. Efficacy of silk vista and silk vista baby

    Assessed by aneurysm occlusion rate

    Time frame: Up to 6 months (-2/+3 months) post- procedure

  12. Efficacy of silk vista and silk vista baby

    Assessed by aneurysm occlusion rate

    Time frame: Up to 12 months (-3 / + 6 months) post procedure

  13. Efficacy of silk vista and silk vista baby

    Assessed by aneurysm occlusion rate

    Time frame: Up to 3 years post procedure

  14. Efficacy of silk vista and silk vista baby

    Assessed by aneurysm occlusion rate

    Time frame: Up to 5 years post procedure

  15. Technical procedure

    The practices related to the use of silk vista baby will be describe

    Time frame: At T0

07

Study locations

29 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Mar 2023, 39 months.

Of 105 observational studies under Intracranial Aneurysm, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 145. This study's 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2019
First posted
Jul 26, 2019
StartActual
Nov 4, 2019
Primary completionActual
Mar 1, 2023
CompletionEst.
Nov 30, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04034810
Lead sponsor
Balt Extrusion
Responsible party
Sponsor
First posted
Jul 26, 2019
Start date
Nov 4, 2019
Primary completion
Mar 1, 2023
Completion
Nov 30, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Mario Martinez Galdamez, Dr
principal investigator · Hospital Clinico Universitario de Valladolid (HCUV), Spain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion